Insider Selling: Enanta Pharmaceuticals Inc (ENTA) Director Sells $153,301.36 in Stock

Enanta Pharmaceuticals Inc (NASDAQ:ENTA) Director Bruce L. A. Carter sold 1,546 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $99.16, for a total transaction of $153,301.36. Following the transaction, the director now owns 1,546 shares of the company’s stock, valued at $153,301.36. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Shares of Enanta Pharmaceuticals stock opened at $102.85 on Friday. Enanta Pharmaceuticals Inc has a twelve month low of $64.08 and a twelve month high of $127.77. The firm has a market capitalization of $1.99 billion, a P/E ratio of 29.55 and a beta of 1.39.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings data on Wednesday, February 6th. The biotechnology company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.46 by ($0.21). Enanta Pharmaceuticals had a return on equity of 22.78% and a net margin of 36.19%. The business had revenue of $69.89 million during the quarter, compared to the consensus estimate of $71.27 million. During the same period in the prior year, the firm earned $0.59 EPS. The business’s revenue for the quarter was up 83.4% compared to the same quarter last year. On average, analysts forecast that Enanta Pharmaceuticals Inc will post 1.51 EPS for the current year.



Several research analysts have recently issued reports on ENTA shares. Zacks Investment Research upgraded shares of Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, November 19th. BidaskClub upgraded shares of Enanta Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Tuesday, November 20th. Oppenheimer set a $100.00 price target on shares of Enanta Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, November 27th. TheStreet downgraded shares of Enanta Pharmaceuticals from a “b-” rating to a “c+” rating in a report on Monday, November 26th. Finally, Berenberg Bank started coverage on shares of Enanta Pharmaceuticals in a report on Thursday, December 13th. They set a “hold” rating and a $80.00 price target for the company. One equities research analyst has rated the stock with a sell rating, four have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus price target of $100.00.

Several institutional investors have recently modified their holdings of ENTA. Vanguard Group Inc boosted its position in Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after acquiring an additional 330,374 shares during the last quarter. Vanguard Group Inc. boosted its position in Enanta Pharmaceuticals by 30.1% during the third quarter. Vanguard Group Inc. now owns 1,426,791 shares of the biotechnology company’s stock valued at $121,934,000 after acquiring an additional 330,374 shares during the last quarter. Matarin Capital Management LLC bought a new stake in Enanta Pharmaceuticals during the third quarter valued at $17,964,000. BlackRock Inc. boosted its position in Enanta Pharmaceuticals by 6.5% during the third quarter. BlackRock Inc. now owns 2,590,166 shares of the biotechnology company’s stock valued at $221,354,000 after acquiring an additional 157,166 shares during the last quarter. Finally, Norges Bank bought a new stake in Enanta Pharmaceuticals during the fourth quarter valued at $7,106,000. 86.20% of the stock is currently owned by institutional investors.

WARNING: “Insider Selling: Enanta Pharmaceuticals Inc (ENTA) Director Sells $153,301.36 in Stock” was posted by Dakota Financial News and is owned by of Dakota Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this piece can be viewed at https://dakotafinancialnews.com/2019/03/15/insider-selling-enanta-pharmaceuticals-inc-enta-director-sells-153301-36-in-stock.html.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, focuses on the research and development of small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, non-alcoholic steatohepatitis, primary biliary cholangitis, and hepatitis B virus.

See Also: Gross Domestic Product (GDP)

Insider Buying and Selling by Quarter for Enanta Pharmaceuticals (NASDAQ:ENTA)

Receive News & Ratings for Enanta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enanta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.